Therapeutically, it is logical to combine MLN4924 with ASCT2 inhibitor for enhanced anti-cancer efficacy, given that neddylation inactivation increases glutamine uptake and metabolism through ASCT2 to sustain the growth of breast cancer cells. Here, SLC1A5 is linked to breast cancer.